Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

Similar articles for PubMed (Select 24724062)

1.

Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the Consortium for Improving Survival of Lymphoma.

Kang BW, Sohn SK, Moon JH, Chae YS, Kim JG, Lee SJ, Kim WS, Lee JJ, Lee SR, Park KU, Lee HS, Lee WS, Won JH, Park MR, Kwak JY, Kim MK, Kim HJ, Oh SY, Kang HJ, Suh C.

Blood Res. 2014 Mar;49(1):15-21. doi: 10.5045/br.2014.49.1.15. Epub 2014 Mar 24.

2.

Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.

Hoster E, Klapper W, Hermine O, Kluin-Nelemans HC, Walewski J, van Hoof A, Trneny M, Geisler CH, Di Raimondo F, Szymczyk M, Stilgenbauer S, Thieblemont C, Hallek M, Forstpointner R, Pott C, Ribrag V, Doorduijn J, Hiddemann W, Dreyling MH, Unterhalt M.

J Clin Oncol. 2014 May 1;32(13):1338-46. doi: 10.1200/JCO.2013.52.2466. Epub 2014 Mar 31.

PMID:
24687837
3.

Outcome prediction of advanced mantle cell lymphoma by international prognostic index versus different mantle cell lymphoma indexes: one institution study.

Todorovic M, Balint B, Andjelic B, Stanisavljevic D, Kurtovic NK, Radisavljevic Z, Mihaljevic B.

Med Oncol. 2012 Sep;29(3):2212-9. doi: 10.1007/s12032-011-0136-1. Epub 2011 Dec 15.

PMID:
22170090
4.

The clinical features, therapeutic responses, and prognosis of the patients with mantle cell lymphoma.

Ying ZT, Zheng W, Wang XP, Xie Y, Tu MF, Lin NJ, Ping LY, Liu WP, Deng LJ, Zhang C, Zhu J, Song YQ.

Chin J Cancer. 2012 Jul;31(7):348-53. doi: 10.5732/cjc.011.10469. Epub 2012 Jun 14.

5.

Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.

Vose JM.

Am J Hematol. 2012 Jun;87(6):604-9. doi: 10.1002/ajh.23176. Review.

PMID:
22615102
6.

Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.

Vose JM.

Am J Hematol. 2013 Dec;88(12):1082-8. doi: 10.1002/ajh.23615. Review.

PMID:
24273091
7.

Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.

Abdelhamid T, Samra M, Ramadan H, Mehessin M, Mokhtar N.

J Egypt Natl Canc Inst. 2011 Mar;23(1):17-24. doi: 10.1016/j.jnci.2011.07.003. Epub 2011 Sep 8.

8.

Modified number of extranodal involved sites as a prognosticator in R-CHOP-treated patients with disseminated diffuse large B-cell lymphoma.

Yoo C, Kim S, Sohn BS, Kim JE, Yoon DH, Huh J, Lee DH, Kim SW, Lee JS, Suh C.

Korean J Intern Med. 2010 Sep;25(3):301-8. doi: 10.3904/kjim.2010.25.3.301. Epub 2010 Aug 31.

9.

Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.

Mangel J, Buckstein R, Imrie K, Spaner D, Crump M, Tompkins K, Reis M, Perez-Ordonez B, Deodhare S, Romans R, Pennell N, Robinson JB, Hewitt K, Richardson P, Lima A, Pavlin P, Berinstein NL.

Semin Oncol. 2002 Feb;29(1 Suppl 2):56-69. Review.

PMID:
11842390
10.

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.

Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, Pfreundschuh M, Reiser M, Metzner B, Einsele H, Peter N, Jung W, Wörmann B, Ludwig WD, Dührsen U, Eimermacher H, Wandt H, Hasford J, Hiddemann W, Unterhalt M; German Low Grade Lymphoma Study Group (GLSG); European Mantle Cell Lymphoma Network.

Blood. 2008 Jan 15;111(2):558-65. Epub 2007 Oct 25. Erratum in: Blood. 2008 Jun 15;111(12):5761.

11.

Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma.

Griffiths R, Mikhael J, Gleeson M, Danese M, Dreyling M.

Blood. 2011 Nov 3;118(18):4808-16. doi: 10.1182/blood-2011-04-348367. Epub 2011 Aug 26.

12.

Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma.

Yoo C, Yoon DH, Kim S, Huh J, Park CS, Park CJ, Lee SW, Suh C.

Hematol Oncol. 2015 Feb 16. doi: 10.1002/hon.2188. [Epub ahead of print]

PMID:
25689467
13.

Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.

Li X, Liu Z, Cao J, Hong X, Wang J, Chen F, Wang C, Zou S, Li J, Shen Z.

Ann Hematol. 2012 Jun;91(6):837-45. doi: 10.1007/s00277-011-1375-0. Epub 2011 Dec 9.

PMID:
22160255
14.

Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype.

Bernard M, Gressin R, Lefrère F, Drénou B, Branger B, Caulet-Maugendre S, Tass P, Brousse N, Valensi F, Milpied N, Voilat L, Sadoun A, Ghandour C, Hunault M, Leloup R, Mannone L, Hermine O, Lamy T.

Leukemia. 2001 Nov;15(11):1785-91.

PMID:
11681422
15.

Mantle cell lymphoma epidemiology: a population-based study in France.

Leux C, Maynadié M, Troussard X, Cabrera Q, Herry A, Le Guyader-Peyrou S, Le Gouill S, Monnereau A.

Ann Hematol. 2014 Aug;93(8):1327-33. doi: 10.1007/s00277-014-2049-5. Epub 2014 Apr 25.

PMID:
24763513
16.

Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database.

Salek D, Vesela P, Boudova L, Janikova A, Klener P, Vokurka S, Jankovska M, Pytlik R, Belada D, Pirnos J, Moulis M, Kodet R, Michal M, Janousova E, Muzik J, Mayer J, Trněný M.

Leuk Lymphoma. 2014 Apr;55(4):802-10. doi: 10.3109/10428194.2013.815349. Epub 2013 Aug 13.

PMID:
23772666
17.

Mantle cell lymphoma in Thai patients.

Intragumtornchai T, Rojnuckarin P, Sutcharitchan P, Wannakrairot P.

J Med Assoc Thai. 2004 Sep;87(9):1071-5.

PMID:
15516008
18.

Central nervous system involvement in mantle cell lymphoma.

Ferrer A, Bosch F, Villamor N, Rozman M, Graus F, Gutiérrez G, Mercadal S, Campo E, Rozman C, López-Guillermo A, Montserrat E.

Ann Oncol. 2008 Jan;19(1):135-41. Epub 2007 Oct 24.

19.

Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.

Romaguera JE, Fayad LE, Feng L, Hartig K, Weaver P, Rodriguez MA, Hagemeister FB, Pro B, McLaughlin P, Younes A, Samaniego F, Goy A, Cabanillas F, Kantarjian H, Kwak L, Wang M.

Br J Haematol. 2010 Jul;150(2):200-8. doi: 10.1111/j.1365-2141.2010.08228.x. Epub 2010 May 26. Review. Erratum in: Br J Haematol.n 2010 Oct;151(1):111.

PMID:
20528872
20.

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).

Geisler CH, Kolstad A, Laurell A, Räty R, Jerkeman M, Eriksson M, Nordström M, Kimby E, Boesen AM, Nilsson-Ehle H, Kuittinen O, Lauritzsen GF, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E; Nordic Lymphoma Group.

Blood. 2010 Feb 25;115(8):1530-3. doi: 10.1182/blood-2009-08-236570. Epub 2009 Dec 23.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk